...
首页> 外文期刊>Advanced drug delivery reviews >RNA therapeutics targeting osteoclast-mediated excessive bone resorption
【24h】

RNA therapeutics targeting osteoclast-mediated excessive bone resorption

机译:针对破骨细胞介导的过度骨吸收的RNA治疗药物

获取原文
获取原文并翻译 | 示例
           

摘要

RNA interference (RNAi) is a sequence-specific post-transcriptional gene silencing technique developed with dramatically increasing utility for both scientific and therapeutic purposes. Short interfering RNA (siRNA) is currently exploited to regulate protein expression relevant to many therapeutic applications, and commonly used as a tool for elucidating disease-associated genes. Osteoporosis and their associated osteoporotic fragility fractures in both men and women are rapidly becoming a global healthcare crisis as average life expectancy increases worldwide. New therapeutics are needed for this increasing patient population. This review describes the diversity of molecular targets suitable for RNAi-based gene knock down in osteoclasts to control osteoclast-mediated excessive bone resorption. We identify strategies for developing targeted siRNA delivery and efficient gene silencing, and describe opportunities and challenges of introducing siRNA as a therapeutic approach to hard and connective tissue disorders.
机译:RNA干扰(RNAi)是一种序列特异性的转录后基因沉默技术,其开发用途广泛,可用于科学和治疗目的。短干扰RNA(siRNA)目前被用于调节与许多治疗应用有关的蛋白质表达,并且通常用作阐明疾病相关基因的工具。随着全球平均寿命的增长,男性和女性的骨质疏松症及其相关的骨质疏松性脆性骨折正迅速成为全球医疗危机。对于这种不断增加的患者群体,需要新的疗法。这篇综述描述了适于破骨细胞中基于RNAi的基因敲低以控制破骨细胞介导的过量骨吸收的分子靶标的多样性。我们确定了开发靶向siRNA传递和有效基因沉默的策略,并描述了将siRNA引入治疗硬性和结缔组织疾病的治疗方法的机遇和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号